US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer

Affiliations

• ¹ Division of Cancer Pharmacology II (DCPII), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
• ² Division of Pharmacometrics (DPM), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
• ³ Division of Cancer Pharmacology I (DCPI), OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.
• ⁴ OCP, OTS, CDER, FDA, Silver Spring, Maryland, USA.